Literature DB >> 1671638

P-glycoprotein drug efflux pump involved in the mechanisms of intrinsic drug resistance in various colon cancer cell lines. Evidence for a saturation of active daunorubicin transport.

E C Spoelstra1, H Dekker, G J Schuurhuis, H J Broxterman, J Lankelma.   

Abstract

We studied the resistance of colon tumors to anticancer agents in vitro. Using daunorubicin (DN), a number of cellular parameters which normally indicate acquired or multidrug resistance (MDR), were compared for several human wild-type colon cell lines, i.e. HT29, SW1116 and COLO 320, and the murine colon cell line C-26. The sensitive/MDR human ovarian cancer cell line couple A2780/2780AD was used as a reference. The amount of P-glycoprotein (P-gp) was in the order HT29, A2780 less than or equal to SW1116 less than C26 less than or equal to COLO 320 less than 2780AD. The MDR modifiers verapamil, Cremophor EL, cyclosporin A and Ro 11-2933/001 had significant effects on DN cytotoxicity, total DN accumulation and efflux, only if P-gp was present. A flow-through system was used to study the mechanism of DN transport. For the first time, evidence for saturation of an active transport of DN from the cells is reported. We discussed the possible presence of cooperative activity between at least two binding sites on the protein responsible for DN efflux, likely to be P-gp.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1671638     DOI: 10.1016/0006-2952(91)90531-9

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  13 in total

1.  Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells.

Authors:  T Minko; P Kopecková; J Kopecek
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

2.  Selective photodepletion of malignant T cells in extracorporeal photopheresis with selenorhodamine photosensitizers.

Authors:  Zachariah A McIver; Mark W Kryman; Young Choi; Benjamin N Coe; Gregory A Schamerhorn; Michelle K Linder; Kellie S Davies; Jacqueline E Hill; Geri A Sawada; Jason M Grayson; Michael R Detty
Journal:  Bioorg Med Chem       Date:  2016-06-02       Impact factor: 3.641

Review 3.  Mechanisms of drug resistance in colon cancer and its therapeutic strategies.

Authors:  Tao Hu; Zhen Li; Chun-Ying Gao; Chi Hin Cho
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

4.  Doxorubicin loaded pH-sensitive micelle: antitumoral efficacy against ovarian A2780/DOXR tumor.

Authors:  Dongin Kim; Eun Seong Lee; Kyeongsoon Park; Ick Chan Kwon; You Han Bae
Journal:  Pharm Res       Date:  2008-05-01       Impact factor: 4.200

5.  Continuous in situ electrochemical monitoring of doxorubicin efflux from sensitive and drug-resistant cancer cells.

Authors:  C Yi; M Gratzl
Journal:  Biophys J       Date:  1998-11       Impact factor: 4.033

6.  Increased doxorubicin levels in hepatic tumors with reduced systemic drug exposure achieved with complete hepatic venous isolation and extracorporeal chemofiltration.

Authors:  S A Curley; D L Stone; G M Fuhrman; D C Hohn; Z H Siddik; R A Newman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  ATP-stimulated electrolyte and mucin secretion in the human intestinal goblet cell line HT29-Cl.16E.

Authors:  D Merlin; C Augeron; X Y Tien; X Guo; C L Laboisse; U Hopfer
Journal:  J Membr Biol       Date:  1994-01       Impact factor: 1.843

8.  Constitutive expression of multidrug resistance in human colorectal tumours and cell lines.

Authors:  R Kramer; T K Weber; B Morse; R Arceci; R Staniunas; G Steele; I C Summerhayes
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

9.  Cortisol is transported by the multidrug resistance gene product P-glycoprotein.

Authors:  C K van Kalken; H J Broxterman; H M Pinedo; N Feller; H Dekker; J Lankelma; G Giaccone
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

10.  In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance.

Authors:  P Mistry; J Plumb; S Eccles; S Watson; I Dale; H Ryder; G Box; P Charlton; D Templeton; P B Bevan
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.